Endocrine Abstracts

Introduction: IDegLira is the first fixed ratio combination of a basal insulin degludec and a glucagon-like peptide-receptor analogue liraglutide. These combination producereduction in glycated hemoglobin A1c (HbA1c) and help to mitigate the weight gain. The aim of this study was to evaluate relationship between change in glycemic parameters and body weight in patients who began therapy with IDegLira.

Patients and Methods: Retrospective study included 86 patients with type 2 diabetes who began therapy with IDeg Lira, previously uncontrolled on basal insulin and metformin, and follow up for 6 months. Patients were devide in two groups according HbA1c: group I with HbA1c <9 (n=50) and group II with HbA1c≥9 (n=46). We examined glycemic parameters (HbA1c, fasting plasma glucose, FPG) and antropomethric parameters (body weight and BMI).

Results: The analysis showed that patients in group II with higher HbA1c from baseline had higher reduction in HbA1c and FPG (0.9% vs. 0.6%, P<0.05 for HbA1c, 1.0 mmol/l vs. 0.6 mmol/l, P<0.05 for FPG ). Patients in all groups had decreased body weight at the end of study. The higher decreased in HbA1c in group II didn’t followed with significance higher weight loss (1.9 kg vs 1.8 kg, P>0.05) and higher reduced BMI (0.8 vs 0.7 kg/m², P>0.05). We founded in both groups a significant direct correlation between reduction HbA1c and BMI (r=0.35, P< 0.05 vs. r=0.42, P<0.05), but with no significant difference between groups. At the end of study, no difference had showed in dosage of IDegLira between groups. Patients with poorer glycemic control from baseline were older and obese according BMI, but with no difference in duration of diabetes.

Conclusion: Our results showed that reduced glycemic parameters and weight loss depends on baseline value with IDegLira. The higher reduction glycemic parameters had no relationship with significantly higher weight loss.

Key words: insulin degludec, liraglutide, weight loss, type 2 diabetes.